The Latest Breaking News from RCUS

The biotech industry's dynamic growth, spurred by government backing and technological advances, addresses rising disease challenges and propels advancements in healthcare. Hence, fundamentally strong biotech stocks Gilead Sciences (GILD), Incyte Corporation (INCY), Jazz Pharmaceuticals (JAZZ), and Exelixis (EXEL) might be solid investments for upcoming year gains. Read more….

As the biotech industry looks well-positioned for solid growth driven by strong government support and a growing foothold of personalized medicines, it could be wise for investors to buy fundamentally strong biotech stocks Gilead Sciences (GILD) and Regeneron Pharmaceuticals (REGN). However, fundamentally weak Titan Pharmaceuticals (TTNP) might be best avoided.…

Arcus Biosciences Inc (NYSE:RCUS) announced results from the third interim analysis of the ongoing Phase 2 ARC-7 study of zimberelimab vs. domvanalimab plus zimberelimab (doublet) vs. domvanalimab plus zimberelimab and etrumadenant (triplet) as a first-line treatment for metastatic non-small cell lung cancer. In this interim analysis, both domvanalimab-containing arms continued to show meaningful…

Arcus Biosciences (NYSE:RCUS) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Arcus Biosciences will report an earnings per share (EPS) of $-0.31.

Arcus Biosciences (NYSE:RCUS) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:10 PM. Here's what investors need to know about the announcement.

Arcus Biosciences (NYSE:RCUS) is set to give its latest quarterly earnings report on Wednesday, 2022-02-23. Here's what investors need to know before the announcement. Analysts estimate that Arcus Biosciences will report an earnings per share (EPS) of $-0.74.